AscellaHealth, a global partner in the specialty pharmaceutical industry, has announced the formation of its International Strategic Advisory Council (ASAC) to assist Life Sciences companies in navigating the complexities of global markets and enhancing access to rare disease therapies. The council aims to strengthen AscellaHealth's strategic leadership across the specialty pharmaceutical value chain, focusing on operational excellence and cost efficiency. Bill Oldham, chairman and president of AscellaHealth, emphasized the need for specialized expertise in light of new regulatory challenges and evolving U.S. policies. The inaugural member of ASAC is Barry O'Dowd, a seasoned life sciences executive with a background in international business development. His experience will help clients identify market opportunities and navigate cross-border complexities. The council also aims to provide insights into local regulatory requirements and reimbursement models, ensuring high-quality patient care. This initiative is part of AscellaHealth's broader commitment to delivering scalable solutions that support innovation and patient access in the life sciences sector.